June 13, 2026 a 01:00 pm
EW: Fundamental Ratio Analysis - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation, a distinguished entity in the medical technology sector, showcases a robust product portfolio catering to structural heart conditions with substantial global operations. The stock's performance is significantly influenced by its innovative product range and an expanding market presence. The analysis provides an insight into its current standing and growth potential within the healthcare domain.
Fundamental Rating
The current rating for Edwards Lifesciences stands at B+, indicating a stable performance with room for improvement across various financial metrics. Below are the specific scores and a visual representation through bars:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
Analysis reveals consistent performance with slight variations in scoring over time. Here's a snapshot comparing past performance with the most recent:
| Date | Overall Score | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | 3 | 4 | 4 | 5 | 3 | 1 | 2 |
| Past Date | 3 | 4 | 4 | 5 | 3 | 1 | 2 |
Analyst Price Targets
The stock's price target analysis demonstrates moderate growth potential, underscored by a blend of contractual highs and lows:
| High | Low | Median | Consensus |
|---|---|---|---|
| $110 | $85 | $95 | $96.83 |
Analyst Sentiment
The sentiment among analysts showcases a predominantly positive stance, favoring stock retention and acquisition:
| Rating Type | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 16 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Edwards Lifesciences Corporation exemplifies a resilient player within the medical technology industry, poised for growth via its ingenious solutions for structural heart diseases. Despite current valuation challenges reflected in low price-to-earnings and price-to-book scores, strong returns on assets and equity, coupled with a positive analyst sentiment, endorse its potential. With a consensus 'Buy' rating and a promising price target median, the risks appear balanced by substantial opportunities in its market segment. Stakeholders should weigh these factors considering both the company's intrinsic strengths and the broader economic environment.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years